Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development

scientific article published on January 2017

Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1111/IMR.12509
P932PMC publication ID5302796
P698PubMed publication ID28133802

P50authorBarton HaynesQ4865631
Mattia BonsignoriQ56808332
David C. MontefioriQ63302725
Hua-Xin LiaoQ88608388
Munir AlamQ89520930
Wilton B WilliamsQ89520935
P2093author name stringFeng Gao
P2860cites workHIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Q37360774
Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogensQ37456354
Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine?Q37519312
An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1.Q37680009
Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responsesQ37718722
Insights into the trimeric HIV-1 envelope glycoprotein structureQ38323609
Sequence-Intrinsic Mechanisms that Target AID Mutational Outcomes on Antibody GenesQ38388195
Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformationQ38959483
Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity MaturationQ38988188
Measuring HIV neutralization in a luciferase reporter gene assayQ39914262
Immune perturbations in HIV-1-infected individuals who make broadly neutralizing antibodiesQ40103798
Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine DesignQ40296420
Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies.Q40429324
Affinity Dependence of the B Cell Response to Antigen: A Threshold, a Ceiling, and the Importance of Off-RateQ41027647
Affinity Maturation of a Potent Family of HIV Antibodies Is Primarily Focused on Accommodating or Avoiding Glycans.Q41037927
Rapid development of broadly influenza neutralizing antibodies through redundant mutationsQ41710834
Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV.Q42215329
Induction of HIV-1 broad neutralizing antibodies in 2F5 knock-in mice: selection against membrane proximal external region-associated autoreactivity limits T-dependent responsesQ42278743
Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variantsQ51926211
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodiesQ24561905
Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individualsQ24635002
Rapid cloning of high-affinity human monoclonal antibodies against influenza virusQ24644672
HIV-Host Interactions: Implications for Vaccine DesignQ26765966
Antibody responses to envelope glycoproteins in HIV-1 infectionQ26991572
HIV‐1 neutralizing antibodies: understanding nature's pathwaysQ27000480
Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 DonorsQ27643993
Maturation Pathway from Germline to Broad HIV-1 Neutralizer of a CD4-Mimic AntibodyQ27644415
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9Q27644478
Co-evolution of a broadly neutralizing HIV-1 antibody and founder virusQ27644501
Developmental pathway for potent V1V2-directed HIV-neutralizing antibodiesQ27644515
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine designQ27644634
Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1Q27662155
Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1Q27662167
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01Q27663293
Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 BindingQ27670829
Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep SequencingQ27671696
Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodiesQ27674878
Initiation of immune tolerance-controlled HIV gp41 neutralizing B cell lineagesQ37221575
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infectionQ37273195
Recognition of synthetic glycopeptides by HIV-1 broadly neutralizing antibodies and their unmutated ancestors.Q37318213
A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan ShieldQ27675032
Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2Q27675879
Rational HIV Immunogen Design to Target Specific Germline B Cell ReceptorsQ27677104
Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120Q27678306
Structural basis for diverse N-glycan recognition by HIV-1–neutralizing V1–V2–directed antibody PG16Q27678312
The Effects of Somatic Hypermutation on Neutralization and Binding in the PGT121 Family of Broadly Neutralizing HIV AntibodiesQ27680688
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralizationQ27684578
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibodyQ27759364
IDEPI: rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platformQ28543211
Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogeniesQ28602877
Antibody neutralization and escape by HIV-1Q29547345
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetQ29547347
Broad neutralization coverage of HIV by multiple highly potent antibodiesQ29615361
Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibodyQ29618366
Rapid evolution of the neutralizing antibody response to HIV type 1 infectionQ29618603
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1Q29619511
Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1Q29619512
Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residuesQ30644992
Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.Q31016954
Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individualsQ33526340
Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic toleranceQ33591736
Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodiesQ33614365
Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1.Q33693391
Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infectionQ33702217
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodiesQ33719511
Early development of broadly neutralizing antibodies in HIV-1-infected infantsQ33764917
Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesQ33911935
Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sortingQ34042758
Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodiesQ34114798
Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogensQ34121215
Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodiesQ34177732
Acute HIV-1 InfectionQ34185814
B-cell-lineage immunogen design in vaccine development with HIV-1 as a case studyQ34273373
A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1Q34306804
Identification of broadly neutralizing antibody epitopes in the HIV-1 envelope glycoprotein using evolutionary modelsQ34455457
Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interfaceQ34473958
Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibodyQ34526404
Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbsQ34539819
The immune response during acute HIV-1 infection: clues for vaccine developmentQ34614862
Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apexQ34709433
Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loopQ34742533
Structural evolution of glycan recognition by a family of potent HIV antibodiesQ34782382
Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremiaQ34848486
HIV-1 envelope gp41 antibodies can originate from terminal ileum B cells that share cross-reactivity with commensal bacteriaQ34957769
Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelopeQ34991017
Structure and immune recognition of trimeric pre-fusion HIV-1 Env.Q35142291
Rescue of HIV-1 broad neutralizing antibody-expressing B cells in 2F5 VH x VL knockin mice reveals multiple tolerance controlsQ35336374
Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestorsQ35382871
Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutatedQ35441583
HIV-1 VACCINES. Diversion of HIV-1 vaccine-induced immunity by gp41-microbiota cross-reactive antibodiesQ35728947
Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infectionQ35857268
Two distinct broadly neutralizing antibody specificities of different clonal lineages in a single HIV-1-infected donor: implications for vaccine designQ35868076
HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogenQ35969973
Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C InfectionQ35974269
Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant VirusesQ36053810
Longitudinal Antigenic Sequences and Sites from Intra-Host Evolution (LASSIE) Identifies Immune-Selected HIV VariantsQ36246646
Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodiesQ36262823
Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escapeQ36388754
New Member of the V1V2-Directed CAP256-VRC26 Lineage That Shows Increased Breadth and Exceptional PotencyQ36433894
HIV TransmissionQ36526615
Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodiesQ36750045
Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodiesQ36760049
Characterization of human IgG repertoires in an acute HIV-1 infectionQ36873507
Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.Q36974754
Common Tolerance Mechanisms, but Distinct Cross-Reactivities Associated with gp41 and Lipids, Limit Production of HIV-1 Broad Neutralizing Antibodies 2F5 and 4E10Q37049675
HIV-1 Neutralizing Antibodies with Limited Hypermutation from an InfantQ37059216
Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strainsQ37123109
Immune Tolerance Negatively Regulates B Cells in Knock-In Mice Expressing Broadly Neutralizing HIV Antibody 4E10Q37171251
Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose PatchQ37213491
P275copyright licenseCreative Commons Attribution-NonCommercialQ6936496
P433issue1
P921main subjectco-evolutionQ208841
HIV vaccineQ1479804
neutralizing antibodyQ7003054
human immunodeficiency virus infectious diseaseQ18556697
HIV type 1Q18907320
P5008on focus list of Wikimedia projectScienceSourceQ55439927
P304page(s)145-160
P577publication date2017-01-01
P13046publication type of scholarly workreview articleQ7318358
P1433published inImmunological ReviewsQ15724582
P1476titleAntibody-virus co-evolution in HIV infection: paths for HIV vaccine development
P478volume275

Reverse relations

cites work (P2860)
Q91967266AIDS Vaccine Research Subcommittee (AVRS) Consultation: Early-Life Immunization Strategies against HIV Acquisition
Q90677040Antibody responses to the HIV-1 envelope high mannose patch
Q90015400B Cell Responses: Cell Interaction Dynamics and Decisions
Q57815702Broadly neutralizing antibodies in HIV-1 treatment and prevention
Q56974226Broadly neutralizing antibodies: What is needed to move from a rare event in HIV-1 infection to vaccine efficacy?
Q92718969Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies
Q94939084CD4 binding loop responsible for the neutralization of human monoclonal neutralizing antibody Y498
Q64982392Characteristics of Envelope Genes in a Chinese Chronically HIV-1 Infected Patient With Broadly Neutralizing Activity.
Q59349684Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes
Q41928050Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era.
Q41611835Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.
Q47852386Developing an HIV vaccine
Q40047250Development of an anti-HIV vaccine eliciting broadly neutralizing antibodies
Q91413247Engineering immunity for next generation HIV vaccines: The intersection of bioengineering and immunology
Q52688325Epitopes for neutralizing antibodies induced by HIV-1 envelope glycoprotein BG505 SOSIP trimers in rabbits and macaques.
Q41936503Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development
Q60913187HIV-1 Neutralizing Antibody Signatures and Application to Epitope-Targeted Vaccine Design
Q59811711HIV-1 immunogens and strategies to drive antibody responses towards neutralization breadth
Q57117718IDLV-HIV-1 Env vaccination in non-human primates induces affinity maturation of antigen-specific memory B cells
Q92242527Identification of Antibodies Targeting the H3N2 Hemagglutinin Receptor Binding Site following Vaccination of Humans
Q59357079Immune Correlate-Guided HIV Vaccine Design
Q92382854Immunization expands B cells specific to HIV-1 V3 glycan in mice and macaques
Q90391919Immunodominance and Antigenic Variation of Influenza Virus Hemagglutinin: Implications for Design of Universal Vaccine Immunogens
Q91421247Immunological mechanisms of inducing HIV immunity in infants
Q89609089Innovations in HIV-1 Vaccine Design
Q52680808Intragastric administration of Lactobacillus plantarum and AT-2-inactivated SIV does not protect Indian rhesus macaques from intra-rectal SIV challenge nor reduce virus replication after transmission.
Q64053755Kappa chain maturation helps drive rapid development of an infant HIV-1 broadly neutralizing antibody lineage
Q64066934Large-scale network analysis reveals the sequence space architecture of antibody repertoires
Q47218587Multi-Envelope HIV-1 Vaccine Development: Two Targeted Immune Pathways, One Desired Protective Outcome.
Q55097658Multivalent Antigen Presentation Enhances the Immunogenicity of a Synthetic Three-Component HIV-1 V3 Glycopeptide Vaccine.
Q90362304OGRDB: a reference database of inferred immune receptor genes
Q38643834Of Mice, Macaques, and Men: Broadly Neutralizing Antibody Immunotherapy for HIV-1.
Q47226779Passive and active antibody studies in primates to inform HIV vaccines.
Q47548910Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.
Q64063774Positive Selection at Key Residues in the HIV Envelope Distinguishes Broad and Strain-Specific Plasma Neutralizing Antibodies
Q64983102Protein and Glycan Mimicry in HIV Vaccine Design.
Q40118226Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies
Q90335423Somatic hypermutation to counter a globally rare viral immunotype drove off-track antibodies in the CAP256-VRC26 HIV-1 V2-directed bNAb lineage
Q64228820Stabilization of the V2 loop improves the presentation of V2 loop-associated broadly neutralizing antibody epitopes on HIV-1 envelope trimers
Q47313525Stabilization of the gp120 V3 loop through hydrophobic interactions reduces the immunodominant V3-directed non-neutralizing response to HIV-1 envelope trimers
Q57091049Stabilizing HIV-1 envelope glycoprotein trimers to induce neutralizing antibodies
Q60303473Structural Constraints at the Trimer Apex Stabilize the HIV-1 Envelope in a Closed, Antibody-Protected Conformation
Q57093739Structural Insights from HIV-Antibody Coevolution and Related Immunization Studies
Q58583636Synthetic HIV V3 Glycopeptide Immunogen Carrying a N334 N-Glycan Induces Glycan-Dependent Antibodies with Promiscuous Site Recognition
Q46180922The Neutralizing Antibody Response To the HIV-1 Env Protein.
Q52581587The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects
Q40144203The mutable vaccine for mutable viruses
Q40354016The quest for an antibody-based HIV vaccine
Q58595201V4 region of the HIV-1 envelope gene mediates immune escape and may not promote the development of broadly neutralizing antibodies
Q90644755VDJbase: an adaptive immune receptor genotype and haplotype database
Q47215738Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models
Q91862934eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody

Search more.